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Summary
This paper shows a case of pregnancy-associated osteo-
porosis (PAO) with seven vertebral compression frac-
tures treated with strontium ranelate and supplementa-
tion of calcium and cholecalciferol. Clinical evaluation,
laboratory and radiological results are analyzed in the
case-report to demonstrate that strontium ranelate is a
good option to restore quickly the value of bone mineral
density in the treatment of a case of PAO.
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Introduction
Pregnancy-associated osteoporosis is a rare condition first
described in 1948 by Albright and Reifenstein (1) character-
ized by changes in calcium homeostasis and in bone metab-
olism that cause fragility fractures in susceptible woman (2).
The incidence is estimated to be only 0.4 cases per 100.000
woman whereas the number of undiagnosed cases is proba-
bly higher (3). Its aetiology and pathogenesis have yet to be
defined. Surely, pregnancy and lactation might have signifi-
cant impact on bone density (4). It is therefore mandatory,
during pregnant-period, consider diagnosis of pregnancy-as-
sociated osteoporosis (PAO) when hip, lumbar or thoracic
spine pain are present. At the moment there are no guide-
lines for the therapy of PAO. All osteoporosis drugs are
mainly licensed for postmenopausal patients and represent
an off-label use in the treatment of premenopausal woman
with PAO.
Case report
A 27-year-old primiparous and breast-feeding Caucasian
woman was referred to our first-aid department 4 months af-
ter a normal vaginal delivery. She presented with acute se-
vere back pain without history of trauma and started nearly 1
month earlier. She also had difficulties in walking that re-
quired hospital admission. The pain was localized to the
back where spasm on vertebral muscles limited the motion.
The severity of pain, according to the Visual Analogic Scale
(VAS) was 10/10. There was no neurological deficiency. Her
medical history revealed that she had menarche at 14 years
of age with regular menstrual cycle. She reported that she
was completely healthy before pregnancy. No osteoporosis-
related risk factors were present. However, it was noted that
she did not take calcium carbonate and cholecalciferol sup-
plementation during the pregnancy and post-partum period.
Only Beta Follitropin drug was taken before pregnancy to
treat infertility. On clinical examination, her height was 165
cm and weight was 63 kg (BMI = 23.1), with a loss of 1 cm
comparing the value before the pregnancy. She also de-
clared that her weight gained through the pregnancy was 14
kg and the birth weight of the male baby was 3850 g. The in-
strumental assessment included X-rays of thoracic and lum-
bar spine, CT and MRI of the whole spine, bone scintigraphy
and dual energy X-ray absorptiometry (DXA) for the evalua-
tion of bone mineral density (BMD). Laboratory tests (includ-
ing serum calcium, phosphate, alkaline phosphatase, thyroid
and parathyroid hormone levels, liver and renal function
tests, FSH, LH, estradiol, progesterone, prolactin, testos-
terone, osteocalcin, vitamin B12, folate, cortisol, growth hor-
mone, ACTH, vitamin D3) were also performed and did not
show any abnormal values. Visual evaluation of CT and MRI
showed 7 fresh vertebral body fractures of thoracic and lum-
bar vertebrae (T1,3,4,7,9 and L2,5) (Figure 1). Tumoral
markers and bone scintigraphy excluded primary or metasta-
tic bone diseases, as well as infectious ones. Bone densito-
metry measured by dual-energy X-ray absorptiometry (DXA)
(Hologic Discovery Wi S/N 84400) was consistent with os-
teoporosis of the lumbar vertebrae (Table 1). The clinical
findings, laboratory and radiological data strengthen the di-
agnosis of PAO. In according to diagnosis, breast-feeding
was terminated and we prescribed calcium carbonate 1,000
mg/day and cholecalciferol 25000 IU/week. After full and ad-
equate explanation to the patient and her written informed
consent in view of off-label-use, a therapy with strontium
ranelate 2,000 mg/day was also started. To control the pain,
bed-rest and non-steroidal anti-inflammatory drugs were
used for the first week then the patient used a thoracolum-
bosacral orthosis (TLSO) to walk. In two weeks the clinical
conditions improved (VAS value 5/10), so we decided to
avoid surgery (kyphoplasty or vertebroplasty) and to contin-
ue with conservative treatment. After 3 months of treatment
new X-rays was performed. These showed a consolidation of
the vertebral fractures without significant spinal deformity.
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The patient was almost free of back pain (VAS value 2/10),
with a noticeable improvement in mobility. The TLSO was
therefore gradually dismissed and she started a rehabilita-
tion program. Six months after the onset of medical treat-
ment, DXA measurements showed that BMD of the patient
increased 17.9% at the lumbar spine and 8.6% at the proxi-
mal femur. The T-score at the total lumbar region regressed
from -3.0 to -1.7 (Table 1). The back pain was completely
absent (VAS value 0/10). After 12 months of medical treat-
ment, another DXA measurements showed that BMD of the
patient increased 31.1% at the lumbar spine and 20,2% at the
proximal femur in respect to the previous control (Table 1). The
patient was free of back-pain (VAS value 0/10). A repeated X-
Rays showed no further vertebral fracture or progressive col-
lapse on the previously fractured vertebrae. The therapy with
strontium ranelate was therefore suspended and only calcium
carbonate and cholecalciferol have been carried on. In the last
follow-up at 36 months after the beginning of treatment, the
DXA-values had stabilised to a constant level (Table 1). All the
medical treatment was therefore stopped.
Discussion
PAO is a very rare condition that can cause fragility frac-
tures. It usually happens during the first pregnancy, mainly in
the third trimester or early post-partum period (5). The caus-
es are not well known, but several hypotheses have been in-
troduced. A positive family history of post-menopausal os-
teoporosis in PAO is seen more frequently than the controls.
This could suggest that some hereditary factors are involved
(5). Another hypothesis is that pregnancy is merely a stres-
sor, which unmasks pre-existing osteoporosis (6). The
change in calcium metabolism during pregnancy may con-
tribute to the cause of PAO (7, 8). Under the normal environ-
ment of pregnancy and lactation, the calcium demand in-
creases and a relative deficiency of calcium can occur (9). In
our case, she did not receive calcium carbonate and chole-
calciferol supplementation during pregnancy and after deliv-
ery. She had neither osteoporosis-related risk factors nor al-
terations in laboratory tests. Before pregnancy, our patient
had a treatment of infertility with Beta Follitropin (Puregon,
synthetic-FSH) for 2 weeks. FSH has been associated with
BMD loss in animal models (10), but a direct effect in woman
has not been demonstrated (11). The treatment with Beta
Follitropin could therefore not be considered as a possible
cause of PAO. We hypothesize that in our patient PAO was
caused by the negative calcium balance during the last
trimester and early postpartum period. Because of the lack
of a definite aetiology, no standard treatment protocol has
been advanced for the treatment of PAO and associated ver-
tebral fractures. Most cases have been managed with con-
servative treatments: bed rest, analgesics, corset applica-
tion, calcium carbonate, cholecalciferol and weaning from
breast feeding (12, 13). Treatment of PAO with antiresorp-
tive agents like calcitonin or bisphosphonates have been re-
ported, with some improvement in both symptoms and BMD
(7, 14, 15). The efficacy of bisphosphonates has been
demonstrated across many randomized clinical trials and/or
meta-analyses in postmenopausal women with osteoporosis.
However, short-term as well as long-term safety and tolera-
bility concerns (i.e. atypical fractures and osteonecrosis of
the jaw) need to be considered (16). Biphosphonates are
agents which accumulate in bone for years and can cross
the placenta (17), the consequences for a possible subse-
quent pregnancy are yet unknown. In contrast, bone anabol-
ic therapy using parathyroid hormone (PTH 1-34, teri-
paratide) for the treatment of severe postmenopausal osteo-
porosis has been shown to significantly reduce the incidence
of vertebral and non-vertebral fracture (16). It is approved for
the treatment of severe postmenopausal osteoporosis for pa-
tients at high risk of fracture but limited to a 2-year course
because of safety concerns with long-term use. Because of
its biological nature and the short half-life, teriparatide
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Figure 1 - MRI in lateral view of patient’s spine demonstrating 7
fresh thoracic and lumbar plate fractures (T1,3,4,7,9 and L2,5) grey
arrows head.
12-ZARATTINI_-  04/07/14  17:28  Pagina 140
seems to be an alternative to bisphosphonates for the treat-
ment of PAO and it was used in some severe cases (18, 19).
Strontium ranelate is a new treatment option for post-meno-
pausal osteoporosis and it is considered a second-line thera-
py for post-menopausal women who cannot tolerate or are
unable to take bisphosphonates. It has a dual effect of re-
ducing bone resorption and increasing bone formation. As a
matter of fact, it produces significant reduction in the risk of
new vertebral and non-vertebral fractures, and increases
both lumbar spine and femoral neck BMD (16). However,
there are no available data at the moment on its effects and
long-term outcome in pre-menopausal women. Only one
case of PAO was treated with strontium ranelate but after a
period of unsuccessful treatment with bisphosphonates (20).
Balancing the advantages and the possible risks of the off-
label-use of strontium ranelate, we interdisciplinary decided
for this new therapeutic option. The decision to use strontium
ranelate instead of bisphosphonates was made to enable
further healthy pregnancies because it is not stored in bone
matrix for years like the bisphosphonates. Beside, there is
no prediction of long-term follow-up adverse events concern-
ing prenatal impairments with the use of strontium ranelate.
We moreover decided not to use teriparatide for different
reasons: our patient did not show a severe osteoporosis and
we were worried about its already mentioned long-term safe-
ty concerns. The results that we obtained were very encour-
aging: remarkable increase of BMD, improvement of the clin-
ical symptoms in few months of treatment, no occurrence of
further fractures. Our case-report shows the successful use
of strontium ranelate, associated with calcium and cholecal-
ciferol, in a case of PAO with several vertebral fractures.
References
1. Albright F, Reifenstein EC Jr. The Parathyroid Glands and Metabolic Bone
Disease: selected studies. Williams and Wilkins, Baltimore, 1948.
2. Hellmeyer I, Hadji P, Ziller V, Wagner U, Schmidt S. Osteoporose in der
Schwangerschaft. Geburtsh Frauenheilk. 2004;64:38-45.
3. Kovacs CS. Calcium and bone metabolism during pregnancy and lac-
tation. J Mammary Gland Biol Neoplasia. 2005;10(2):105-18. 
4. Drinkwater BL, Chesnut CH 3rd. Bone density changes during pregnancy
and lactation in active women: a longitudinal study. Bone Miner. 1991;1
4(2):153-60. 
5. Dunne F, Walters B, Marshall T, Heath DA. Pregnancy associated os-
teoporosis. Clin Endocrinol (Oxf). 1993;39(4):487-90. 
6. Khastgir G, Studd JW, King H, Abdalla H, Jones J, Carter G, Alaghband-
Zadeh J. Changes in bone density and biochemical markers of bone
turnover in pregnancy-associated osteoporosis. Br J Obstet Gynaecol.
1996;103(7):716-8.
7. Di Gregorio S, Danilowicz K, Rubin Z, Mautalen C. Osteoporosis with ver-
tebral fractures associated with pregnancy and lactation. Nutrition.
2000;16(11-12):1052-5.
8. Kaur M, Pearson D, Godber I, Lawson N, Baker P, Hosking D. Longi-
tudinal changes in bone mineral density during normal pregnancy. Bone.
2003;32(4):449-54.
9. Yoon BK, Lee JW, Choi DS, Roh CR, Lee JH. Changes in biochemical
bone markers during pregnancy and puerperium. J Korean Med Sci.
2000;15(2):189-93.
10. Sun L, Peng Y, Sharrow A, Iqbal J, Zhang Z, Papachristou DJ, Zaidi S,
Zhu LL, Yaroslavskiy BB, Zhou H, Zallone A, Sairam MR, Kumar TR, Bo
W, Braun J, Cardoso-Landa L, Schaffler MB, Moonga BS, Blair HC, Zai-
di M. FSH directly regulates bone mass. 2006;125:247-60.
11. Gourlay ML, Specker BL, Li C, Hammett-Stabler CA, Renner JB, Rubin
JE, et al. Follicle-stimulating hormone is independently associated with
lean mass but not BMD in younger postmenopausal women. Bone.
2012;50(1):311-6. Epub 2011 Nov 7.
12. Khovidhunkit W, Epstein S. Osteoporosis in pregnancy. Osteoporos Int.
1996;6(5):345-54.
13. Phillips AJ, Ostlere SJ, Smith R. Pregnancy-associated osteoporosis: does
the skeleton recover? Osteoporos Int. 2000;11(5):449-54.
14. Hellmeyer L, Kühnert M, Ziller V, Schmidt S, Hadji P. The use of i.v. bis-
phosphonate in pregnancy-associated osteoporosis—case study. Exp
Clin Endocrinol Diabetes. 2007;115(2):139-42.
15. O’Sullivan SM, Grey AB, Singh R, Reid IR. Bisphosphonates in pregnancy
and lactation-associated osteoporosis. Osteoporos Int. 2006;17(7):1008-12.
16. Silverman S, Christiansen C. Individualizing osteoporosis therapy. Os-
teoporos Int. 2012;23:797-809.
17. Ornoy A, Wajnberg R, Diav-Citrin O. The outcome of pregnancy following
pre- pregnancy or early pregnancy alendronate treatment. Reprod Tox-
icol. 2006;22(4):578-9. 
18. Hellmeyer L, Boekhoff J, Hadji P. Treatment with teriparatide in a patient
with pregnancy-associated osteoporosis. Gynecol Endocrinol. 2010
Oct;26(10):725-8.
19. Stumpf UC, Kurth AA, Windolf J, Fassbender WJ. Pregnancy-associat-
ed osteoporosis: an underestimated and underdiagnosed severe disease.
A review of two cases in short- and long-term follow-up. Adv Med Sci.
2007;52:94-7.
20. Tanriover MD, Oz SG, Sozen T, Kilicarslan A, Guven GS. Pregnancy-
and lactation-associated osteoporosis with severe vertebral deformities:
can strontium ranelate be a new alternative for the treatment? Spine J.
2009;9(4):e20-4.
Clinical Cases in Mineral and Bone Metabolism 2014; 11(2): 139-141 141
Pregnancy-associated osteoporosis with seven vertebral compression fractures, a case treated with strontium ranelate
Table 1 - Bone mineral density (BMD), T- and Z-score of the lumbar spine and proximal femur.
Before treatment 6 months of treatment 12 months of treatment Follow-up at 36 months
Lumbar spine BMD 0.624 0.736 0.965 1.026
T-score -3.0 -1.7 -0.8 - 0.7
Z-score -2.9 -1.6 -0.8 - 0.6
Proximal femur BMD 0.721 0.783 0.941 0.950
T-score -1.0 -0.6 -0.0 - 0.0
Z-score -1.0 -0.6 -0.0 - 0.0
BMD values are given as absolute values (g/cm2), T- and Z-score are in respect to average normal values.
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